$-1.16 EPS Expected for Alder Biopharmaceuticals, Inc. (ALDR)

July 14, 2018 - By Kristen Paramore

Analysts expect Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) to report $-1.16 EPS on August, 14.They anticipate $0.32 EPS change or 21.62 % from last quarter’s $-1.48 EPS. After having $-1.73 EPS previously, Alder Biopharmaceuticals, Inc.’s analysts see -32.95 % EPS growth. The stock increased 3.77% or $0.7 during the last trading session, reaching $19.25. About 774,093 shares traded. Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) has declined 8.80% since July 14, 2017 and is downtrending. It has underperformed by 21.37% the S&P500.

Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) Ratings Coverage

Among 4 analysts covering Alder Biopharmaceuticals (NASDAQ:ALDR), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Alder Biopharmaceuticals had 5 analyst reports since January 30, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, June 27 by Needham. As per Wednesday, May 9, the company rating was maintained by BMO Capital Markets. The rating was maintained by Canaccord Genuity with “Buy” on Tuesday, January 30. The rating was maintained by Canaccord Genuity on Thursday, February 8 with “Buy”.

Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States, Australia, and Ireland. The company has market cap of $1.31 billion. The company's lead product candidate includes ALD403, an antibody, which is in Phase II clinical trial to target calcitonin gene-related peptide for the prevention of migraine. It currently has negative earnings. It also develops ALD1910, a genetically engineered monoclonal antibody that is in preclinical study for the treatment of migraine; and Clazakizumab, an antibody, which has been completed Phase IIb clinical trial that inhibits the pro-inflammatory cytokine interleukin-6 for the treatment of rheumatoid and psoriatic arthritis.

More news for Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) were recently published by: Fool.com, which released: “Here’s Why Alder Biopharmaceuticals Is Rising Today” on June 15, 2018. Globenewswire.com‘s article titled: “Report: Developing Opportunities within Newfield Exploration, Heritage Insurance, AptarGroup, Alder …” and published on June 29, 2018 is yet another important article.

Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: